Latest Breaking News On - Protalix bio - Page 1 : comparemela.com

ShockWave Medical, Inc. (NASDAQ: SWAV) Verastem, Inc. (NASDAQ: VSTM) Down In The Dumps Akoya Biosciences, Inc. (NASDAQ: AKYA) Decibel Therapeutics, Inc. (NASDAQ: DBTX) IRadimed Corporation (NASDAQ: IRMD) Lucira Health, Inc. (NASDAQ: LHDX) Mesoblast Limited (NASDAQ: MESO) Protara Therapeutics, Inc. (NASDAQ: TARA) PTC Therapeutics, Inc. (NASDAQ: PTCT) Stocks In Focus Adverum Shares Sink On Serious Adverse Event  Adverum Biotechnologies, Inc. (NASDAQ: ADVM) announced a suspected unexpected serious adverse reaction of hypotony, which is clinically relevant decrease in ocular pressure, in its INFINITY clinical trial evaluating ADVM-022 gene therapy for the treatment of diabetic macular edema. This event occurred 30 weeks after randomization in one patient treated with a single intravitreal injection of the high dose of ADVM-022 who has developed hypotony, with panuveitis and loss of vision in the treated eye.

United statesAuburn hillsDominican republicProtalix bioAxonics incJabil incAmerican society of gene cell therapyArdelyx incBiogen incNuvasive incTherapeutics incCelcuity incModerna incMimedx group incGalera therapeutics incMacrogenics inc